[177Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells.

Detalles Bibliográficos
Publicado en:European Journal of Nuclear Medicine & Molecular Imaging Vol. 32; no. 12; pp. 1457 - 1463
Autores principales: Persson, Mikael, Tolmachev, Vladimir, Andersson, Karl, Gedda, Lars, Sandström, Mattias, Carlsson, Jörgen
Formato: Journal Article
Publicado: Springer Nature Dec2005
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104325254&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 104325254
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        16197070
        NPC
      jtl: European Journal of Nuclear Medicine & Molecular Imaging
      issn: 16197070
      maglogo: N
    pubinfo:
      dt: Dec2005
      vid: 32
      iid: 12
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        104325254
        2011946502
        10.1007/s00259-005-1902-0
        104325254
      ppf: 1457
      ppct: 6
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: [177Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells.
      aug:
        au:
          Persson, Mikael
          Tolmachev, Vladimir
          Andersson, Karl
          Gedda, Lars
          Sandström, Mattias
          Carlsson, Jörgen
        affil: Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; Experimental Urology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
      sug:
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N